Study to Evaluate the Immunogenicity & Safety of GlaxoSmithKline (GSK)

See also
Status	Clinical Trial	Phase
Completed	`NCT03120364` - Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over	Phase 3
Completed	`NCT01165203` - Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects	Phase 2
Recruiting	`NCT06088745` - A Phase Ⅲ Clinical Study to Evaluate Protective Efficacy and Safety of a Recombinant Herpes Zoster Vaccine	Phase 3
Completed	`NCT01385566` - A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2)	Phase 1
Completed	`NCT01137669` - ZOSTAVAX® in Renal Transplant Patients	Phase 1
Completed	`NCT01911065` - T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020	Phase 4
Completed	`NCT00550745` - ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)	Phase 4
Completed	`NCT01132716` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions	N/A
Completed	`NCT01132729` - Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions	N/A
Completed	`NCT00231816` - A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)	Phase 3
Completed	`NCT02852876` - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food	Phase 1
Completed	`NCT05082688` - Age Differences in Influenza and Herpes Zoster Vaccine Responses (INFLUENZA-SHINGRIX)	Phase 2
Completed	`NCT04099706` - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT	N/A
Active, not recruiting	`NCT04091451` - A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) Who Had Prior Episode of Shingles	Phase 3
Completed	`NCT02519855` - Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)	Phase 3
Completed	`NCT04523246` - Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents	Early Phase 1
Completed	`NCT05047770` - A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine	Phase 3
Completed	`NCT03314103` - Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age	Phase 3
Completed	`NCT01527370` - Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)	Phase 3
Recruiting	`NCT05952271` - Herpes Zoster Hospitalizations in Italy

NCT number	NCT01954251
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	October 3, 2013
Completion date	March 20, 2015

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms